Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.
Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.
复制标题
DOI：
10.1001/archopht.1990.01070080058036
复制
发表时间：
1990
影响因子：
--
通讯作者：
T. Meredith;P. Sternberg;J. M. Brown;R. Murphy;S. Fine;A. Schachat;M. Elman;N. Bressler;J. Haller;P. Orr;J. Starr;K. MacMillan;L. Singerman;T. Rice;M. Novak;S. Smith-Brewer;D. Preseren;G. Fish;B. Jost
中科院分区：
文献类型：
--
作者：
T. Meredith;P. Sternberg;J. M. Brown;R. Murphy;S. Fine;A. Schachat;M. Elman;N. Bressler;J. Haller;P. Orr;J. Starr;K. MacMillan;L. Singerman;T. Rice;M. Novak;S. Smith-Brewer;D. Preseren;G. Fish;B. Jost
与年龄相关的黄斑变性研究-Krypton激光器（AMDS-K）是一项多中心对照临床试验，旨在确定Krypton红色激光光学对防止具有脉络性变性的眼睛视力丧失的视力丧失具有脉络性变性1到199个1至199微米从凹起的血管区中心或脉络膜新生血管形成200微米或距离距离凹起的血管区中心，带有血液和/或阻塞的荧光，在凹起的血管区中心的200微米范围内延伸。招募于1987年12月结束后，在247例患者被分配到光凝后，未分配249名患者。在随机分组后的3年中，有49％（86/174）的眼睛与58％（98/169）的未经处理的眼睛相反，失去了六个或更多的视力。当时治疗和未经处理的眼睛的平均视力分别为20/200和20/250。在没有高血压证据的患者中，激光治疗的好处最大，在血压高度升高和/或使用降压药升高的患者中，没有明显的好处。建议在没有高血压的患者眼中符合AMDS-K资格标准的病变治疗。但是，对于患有与AMDS-K中入学的患者相似的明确高血压患者，不能统一治疗。
The Age-Related Macular Degeneration Study-Krypton Laser (AMDS-K) is a multicenter controlled clinical trial designed to determine whether krypton red laser photocoagulation is of value in preventing visual acuity loss in eyes with macular degeneration that have either choroidal neovascularization 1 to 199 microns from the center of the foveal avascular zone or choroidal neovascularization 200 microns or farther from the foveal avascular zone center with blood and/or blocked fluorescence extending within 200 microns of the foveal avascular zone center. Recruitment ended in December 1987 after 247 patients had been assigned to photocoagulation and 249 patients had been assigned to no treatment. At 3 years after randomization, 49% (86/174) of treated eyes, in contrast to 58% (98/169) of untreated eyes, had lost six or more lines of visual acuity. The average visual acuity of treated and untreated eyes at that time was 20/200 and 20/250, respectively. The benefit of laser treatment was largest among patients without evidence of hypertension and diminished to no apparent benefit among patients who had highly elevated blood pressure and/or used antihypertensive medication. Treatment of lesions meeting the AMDS-K eligibility criteria in eyes of patients with no hypertension is recommended. However, treatment cannot be recommended uniformly for patients with definite hypertension having lesions similar to those of patients enrolled in the AMDS-K.